Latest Period
Q4 2025
Security Snapshot
enVVeno Medical Corp - Common Stock, $0.00001 par value (NVNO) Institutional Ownership
CUSIP: 29415J106
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
36
Shares (Excl. Options)
6,556,240
Price
$0.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Symbol
- NVNO on Nasdaq
- Shares outstanding
- 20,505,656
- Price per share
- $0.34
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 6,556,240
- Total reported value
- $2,102,925
- % of total 13F portfolios
- 0%
- Share change
- +494,377
- Value change
- +$127,120
- Number of holders
- 36
- Price from insider filings
- $0.34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NVNO - enVVeno Medical Corp - Common Stock, $0.00001 par value is tracked under CUSIP 29415J106.
- 36 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 36 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $2,102,925 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 36 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 29415J106?
CUSIP 29415J106 identifies NVNO - enVVeno Medical Corp - Common Stock, $0.00001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29415J106:
Significant Owners of enVVeno Medical Corp - Common Stock, $0.00001 par value (NVNO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | $737,465 | 2,048,515 | Perceptive Advisors LLC | 31 Dec 2025 | |||
| SATTERFIELD THOMAS A JR | 9% | $1,348,650 | 1,822,500 | Thomas A. Satterfield, Jr. | 14 Nov 2025 | |||
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 7.1% | $5,804,044 | 1,359,261 | Kingdon Capital Management, L.L.C. | 02 Sep 2025 | |||
| Nantahala Capital Management, LLC | 3.5% | -51% | $624,180 | -$540,807 | 688,940 | -46% | Nantahala Capital Management, LLC | 30 Sep 2025 |
As of 31 Dec 2025, 36 institutional investors reported holding 6,556,240 shares of enVVeno Medical Corp - Common Stock, $0.00001 par value (NVNO). This represents 32% of the company’s total 20,505,656 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of enVVeno Medical Corp - Common Stock, $0.00001 par value (NVNO) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 8.6% | 1,759,035 | 0% | 0.01% | $564,298 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 6.2% | 1,265,845 | -6.9% | 0.06% | $406,083 |
| CM Management, LLC | 6.1% | 1,250,000 | +108% | 0.34% | $401,000 |
| VANGUARD GROUP INC | 1.5% | 299,246 | -65% | 0% | $96,058 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.98% | 201,244 | 0% | 0% | $64,566 |
| GSA CAPITAL PARTNERS LLP | 0.97% | 198,592 | +1380% | 0.01% | $64,000 |
| JPMORGAN CHASE & CO | 0.89% | 182,303 | -0.01% | 0% | $58,483 |
| JANE STREET GROUP, LLC | 0.87% | 178,855 | +149% | 0% | $57,377 |
| TWO SIGMA INVESTMENTS, LP | 0.78% | 159,619 | 0% | $51,206 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.65% | 132,325 | -14% | 0% | $42,450 |
| ACT CAPITAL MANAGEMENT, LLC | 0.56% | 115,000 | 0% | 0.03% | $36,892 |
| SIMPLEX TRADING, LLC | 0.45% | 93,082 | +577% | 0% | $29,879 |
| Westside Investment Management, Inc. | 0.45% | 92,650 | -56% | 0% | $29,726 |
| Virtu Financial LLC | 0.36% | 73,878 | 0% | $24,000 | |
| XTX Topco Ltd | 0.33% | 67,187 | +60% | 0% | $21,554 |
| TWO SIGMA SECURITIES, LLC | 0.31% | 62,582 | +343% | 0% | $20,076 |
| BlackRock, Inc. | 0.29% | 60,474 | +1% | 0% | $19,400 |
| RENAISSANCE TECHNOLOGIES LLC | 0.25% | 51,300 | +76% | 0% | $16,457 |
| HRT FINANCIAL LP | 0.24% | 49,234 | -11% | 0% | $15,000 |
| CITADEL ADVISORS LLC | 0.21% | 42,726 | -22% | 0% | $13,707 |
| STATE STREET CORP | 0.2% | 40,800 | 0% | 0% | $13,089 |
| NORTHERN TRUST CORP | 0.19% | 38,081 | 0% | 0% | $12,216 |
| Fermata Advisors, LLC | 0.16% | 32,717 | -13% | 0% | $10,496 |
| UBS Group AG | 0.16% | 32,121 | +213% | 0% | $10,311 |
| Creative Planning | 0.1% | 20,905 | -45% | 0% | $6,706 |
Institutional Holders of enVVeno Medical Corp - Common Stock, $0.00001 par value (NVNO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$555,992 | $0.34 | 0 |
| 2025 Q4 | 6,556,240 | $2,102,925 | +$127,120 | $0.32 | 36 |
| 2025 Q3 | 5,965,202 | $5,403,122 | -$2,803,262 | $0.91 | 36 |
| 2025 Q2 | 5,079,935 | $20,269,051 | +$6,075,451 | $3.99 | 36 |
| 2025 Q1 | 3,640,381 | $9,573,837 | -$1,748,914 | $2.63 | 30 |
| 2024 Q4 | 4,263,270 | $12,878,793 | -$3,370,239 | $3.02 | 35 |
| 2024 Q3 | 5,209,889 | $17,503,055 | +$5,731,334 | $3.36 | 35 |
| 2024 Q2 | 3,289,256 | $17,267,988 | -$1,696,568 | $5.25 | 25 |
| 2024 Q1 | 3,643,857 | $19,822,808 | -$2,947,912 | $5.44 | 31 |
| 2023 Q4 | 4,248,631 | $21,838,067 | +$10,299,470 | $5.14 | 29 |
| 2023 Q3 | 1,931,716 | $10,411,381 | +$240,978 | $5.39 | 23 |
| 2023 Q2 | 1,917,021 | $5,904,248 | +$322,837 | $3.08 | 22 |
| 2023 Q1 | 1,812,147 | $8,498,422 | +$709,547 | $4.68 | 18 |
| 2022 Q4 | 1,659,323 | $8,461,848 | -$813,295 | $5.10 | 22 |
| 2022 Q3 | 2,185,470 | $13,727,584 | +$305,043 | $6.28 | 20 |
| 2022 Q2 | 2,145,805 | $8,111,390 | +$183,530 | $3.78 | 20 |
| 2022 Q1 | 2,038,463 | $12,985,879 | -$292,702 | $6.37 | 20 |
| 2021 Q4 | 2,080,875 | $13,711,600 | +$13,093,583 | $6.59 | 23 |
| 2021 Q3 | 12,207 | $127,000 | +$127,000 | $10.40 | 1 |